Phio Pharma reported FY 2025 results, ending the year with cash and cash equivalents of USD 21.0 million as of December 31, 2025. Net loss for FY 2025 was USD 8.7 million, or USD 1.45 per share, while total operating expenses were USD 9.2 million. Research and development expenses rose 27% to USD 4.6 million and general and administrative expenses increased 23% to USD 4.6 million. For business updates, Phio Pharma said treatment in the Phase 1b dose-escalation trial of its lead candidate PH-762 was completed with favorable safety, tolerability and pathology data, with the study fully enrolled in November 2025 with 22 patients. The company said an FDA submission seeking guidance on next clinical-study steps for PH-762 is targeted for Q2 2026. Phio Pharma also said 2025 equity financings and warrant exercises generated USD 23.7 million in net proceeds, extending its cash runway into the first half of 2027, and noted new PH-762 data presentations during 2025 at multiple scientific conferences.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202603051605NEWSFILECNPR____20260305_286264_1) on March 05, 2026, and is solely responsible for the information contained therein.
Comments